William Blair Estimates Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Stock analysts at William Blair issued their Q4 2024 EPS estimates for Upstream Bio in a research note issued on Tuesday, November 5th. William Blair analyst M. Phipps forecasts that the company will earn ($0.42) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Upstream Bio’s FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Upstream Bio in a research report on Tuesday. They issued an “overweight” rating and a $38.00 price target for the company. Piper Sandler initiated coverage on Upstream Bio in a report on Tuesday. They issued an “overweight” rating and a $75.00 target price for the company. Finally, TD Cowen began coverage on Upstream Bio in a report on Tuesday. They set a “buy” rating on the stock.

Upstream Bio Price Performance

Shares of UPB stock opened at $27.02 on Thursday. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $29.46.

Insider Buying and Selling

In other Upstream Bio news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the purchase, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Upstream Bio news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the acquisition, the insider now directly owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Erez Chimovits purchased 825,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the purchase, the director now directly owns 4,554,873 shares of the company’s stock, valued at $77,432,841. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.